In the current landscape of healthcare M&A, identifying a practice’s true valuation requires moving beyond surface-level spreadsheets. While adjusted EBITDA serves as the gold standard for initial pricing, it often masks the underlying liquidity constraints caused by insurance reimbursement delays. For both buyers and sellers, the strategic advantage lies in bridging the gap between accrual-basis earnings and actual cash on hand.
Decoding the Gold Standard: EBITDA vs. Real Cash Flow
Valuation multiples for medical practices in 2026 typically range from 4x to 12x EBITDA, according to American Hospital Association (AHA) industry benchmarks. From the buyer’s side, a strong EBITDA story can support deal confidence, but it can also hide revenue-cycle friction and collection delays. From the seller’s side, adjusted EBITDA is often used to demonstrate the full earnings power of the practice, especially when ownership has absorbed personal or one-time expenses that may not continue after closing. Distinguishing between normalized earnings and sustainable free cash flow is vital for long-term financial health.
Step 3: Evaluate Financials and Valuation
A key negotiation point in any healthcare acquisition is the seller’s effort to maximize EBITDA add-backs. That instinct is not automatically unreasonable. Many owners have personally funded growth initiatives, covered above-market staffing during expansion, or run discretionary expenses through the business while building enterprise value. In that context, seller add-backs may reflect real investments made to strengthen the platform. Still, buyers need disciplined verification. ✅ Recast earnings carefully. ✅ Test every adjustment against normalized trailing twelve months methodology and current operating reality. ✅ Separate one-time items from recurring costs that will continue post-close. This expert-to-expert review creates clarity, certainty, and a more defensible valuation.
Leveraging AR-Backed Working Capital for Stability
Whether you are buying or selling, AR-Backed Working Capital can strengthen the transaction. Buyers can use it to support post-close operations, protect liquidity, and fund integration without relying solely on personal credit metrics. Sellers benefit when a buyer has access to scalable capital backed by the aggregate Accounts Receivable balance, which can reduce closing friction and improve confidence in near-term working capital. Under our non-notification lending model, the practice owner remains in full control of billing and collections; White Coat Financial Partners does not take possession of receivables or contact patients. Repayment is structured to align with cash flow, with a clear schedule tied to how the practice actually gets paid. This capital optimization strategy provides the certainty needed to fund immediate operations and practice optimization initiatives.
Strategic Advantage Through Capital Optimization
At White Coat Financial Partners, we provide white-glove services that pair financing with LEAN Six Sigma process improvements to shorten billing cycles and reduce the long-term need for financing. Whether you are scaling a solo clinic, acquiring a multi-location group, or preparing a practice for sale, our solutions provide the strategic advantage to close deals with confidence.
✅ Capital Optimization
🏥 M&A Support
🩺 Practice Stability
Unlock your practice’s potential today. Contact White Coat Financial Partners at https://thewhitecoatadvantage.com or call 910-688-5077.
Author: Stuart D. Anderson
President, White Coat Financial Partners
About the Author
Stuart D. Anderson is the founder and President of White Coat Financial Partners, a Fayetteville, NC-based firm providing specialized financial and advisory services for healthcare professionals and organizations. With deep expertise in AR-backed working capital, M&A brokerage, and Lean Six Sigma process optimization, Stuart helps medical practices unlock capital, streamline operations, and achieve long-term financial stability. Connect with Stuart on LinkedIn.